ALPHATEC HOLDINGS Reports Second Quarter Earnings for FY2023

August 13, 2023

🌥️Earnings Overview

On August 3 2023, ALPHATEC HOLDINGS ($NASDAQ:ATEC) reported their results for the second quarter of FY2023 ending June 30 2023. Compared to the same period last year, total revenue saw a 38.9% rise to USD 116.9 million, while net income decreased from -37.3 million to -51.4 million.

Market Price

The stock opened at a price of $17.0 and closed at $16.9, a decrease of 1.5% from the previous closing price of $17.1. In the second quarter, ALPHATEC HOLDINGS saw an increase in revenue and net income from the first quarter. This growth was driven by strong sales of the company’s products in the medical technology space. The company’s management stated that it is confident that it will continue to experience strong revenue growth in the upcoming quarters.

They also stated that they remain committed to providing innovative products and services to their customers. Investors should continue to watch this company as it looks to build on its success and further expand its presence in the medical technology industry. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Alphatec Holdings. More…

    Total Revenues Net Income Net Margin
    421.81 -167.34 -36.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Alphatec Holdings. More…

    Operations Investing Financing
    -59.3 -122.84 175.48
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Alphatec Holdings. More…

    Total Assets Total Liabilities Book Value Per Share
    628.23 656.39 -0.23
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Alphatec Holdings are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    51.5% -37.2%
    FCF Margin ROE ROA
    -30.1% 226.5% -15.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have analyzed the fundamentals of ALPHATEC HOLDINGS and put together the following report. Our Star Chart shows that ALPHATEC HOLDINGS is strong in assets and growth, but weak in dividends and profitability. We have classified ALPHATEC HOLDINGS as a ‘cheetah’ company, one that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for high returns may be interested in such a company. However, ALPHATEC HOLDINGS’ low health score of 2/10 with regard to its cashflows and debt means it is less likely to safely ride out a crisis without the risk of bankruptcy. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The company’s competitors include Titan Medical Inc, Xtant Medical Holdings Inc, and Modular Medical Inc.

    – Titan Medical Inc ($TSX:TMD)

    Titan Medical Inc is a medical device company that develops, manufactures and sells robotic surgical systems for use in minimally invasive surgery. The company has a market cap of 68.04M as of 2022 and a Return on Equity of -55.6%. Titan Medical Inc’s products are designed to provide surgeons with enhanced visualization, dexterity and access to the surgical site. The company’s products are used in a variety of surgical procedures, including general surgery, urology, gynecology, colorectal surgery and bariatrics.

    – Xtant Medical Holdings Inc ($NYSEAM:XTNT)

    Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development and commercialization of regenerative medicine products and platforms for the treatment of orthopedic injuries and diseases. The company’s product portfolio includes biologic scaffolds, bone graft substitutes, and other regenerative medicine products for use in spine, hip, knee, hand, foot and extremity, and sports medicine procedures. Xtant Medical’s products are sold in over 50 countries worldwide.

    Xtant Medical has a market cap of 69.28M as of 2022 and a Return on Equity of -14.12%. The company is focused on the design, development and commercialization of regenerative medicine products and platforms for the treatment of orthopedic injuries and diseases. Xtant Medical’s products are sold in over 50 countries worldwide.

    – Modular Medical Inc ($NASDAQ:MODD)

    Modular Medical Inc is a healthcare company that provides medical products and services. The company has a market cap of 32.74M as of 2022 and a Return on Equity of -84.42%. Modular Medical Inc’s products and services include medical devices, diagnostic products, and health services. The company operates in the United States, Europe, Asia, and Africa.

    Summary

    Alphatec Holdings reported their second quarter of FY2023 earnings results. Total revenue increased by 38.9% to USD 116.9 million year over year, but net income decreased from -37.3 million to -51.4 million. This suggests that the company is continuing to grow, but there is still a need for more efficient operations and cost savings initiatives to improve profitability. Investors should watch for any future changes in management strategies or operations that may help improve earnings and profitability.

    Additionally, since the share price has decreased due to the net income decline, now may be an opportune time for investors to consider entering into positions in Alphatec Holdings.

    Recent Posts

    Leave a Comment